Straits Times Index
3,324.53 +17.09 (+0.52%) S&P 500
5,421.03 +45.71 (+0.85%) Dow
38,712.21 -35.21 (-0.09%) Nasdaq
17,608.44 +264.89 (+1.53%) Bitcoin USD
67,729.97 -227.65 (-0.33%) CMC Crypto 200
1,420.65 +7.70 (+0.54%)
AZN Jul 2024 80.000 put
| Previous close | 2.0400 |
| Open | 2.1500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 80.00 |
| Expiry date | 2024-07-19 |
| Day's range | 2.0400 - 2.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireFARXIGA approved in the US for the treatment of pediatric type-2 diabetes
WILMINGTON, Del., June 12, 2024--AstraZeneca’s FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.1 The FDA approval was based on positive results from the pediatric T2NOW Phase III trial.2 FARXIGA was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycemic control.1
ZacksAre You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Insider MonkeyWhy AstraZeneca plc (NASDAQ:AZN) is Investors’ One of Favorite International Dividend Stock?
We recently compiled a list of 12 Best International Dividend Stocks to Buy Now. Since AstraZeneca plc (NASDAQ:AZN) ranks higher on our list, we have analyzed the stock in detail. As we move toward the second half of 2024, investors are eagerly preparing for the direction that the stock market will take for the remainder of […]
